Chemical Composition And Its Delivery For Lowering The Risks Of Alzheimer's, Cardiovascular And Type -2 Diabetes Diseases

Abstract

Chemical compositions of bioactive compounds and / or bioactive molecules for lowering the risks of Alzheimer's, Cardiovascular and Diabetes diseases are described. Targeted, passive and programmable / active deliveries of the bioactive compounds and / or bioactive molecules are described. Many embodiments of various subsystems for detection of disease specific biomarkers / an array of disease specific biomarkers and programmable / active delivery of the bioactive compounds and / or bioactive molecules in near real-time / real-time are also described. A portable internet appliance, a portable internet cloud appliance and an augmented reality personal assistant subsystem are also described along with various applications.

Description

CROSS REFERENCE OF RELATED APPLICATIONS[0001]The present application claims priority to: U.S. Provisional Patent Application No. 61 / 957,343 entitled “AUGMENTED REALITY PERSONAL ASSISTANT”, filed on Jul. 1, 2013. The present application is a continuation-in-part (CIP) of U.S. Non-Provisional patent application Ser. No. 13 / 448,378 entitled “SYSTEM AND METHOD FOR INTELLIGENT SOCIAL COMMERCE”, filed on Apr. 16, 2012. Furthermore, the present application is a continuation-in-part (CIP) of U.S. Non-Provisional patent application Ser. No. 13 / 663,376 entitled “CHEMICAL COMPOSITION AND ITS DELIVERY FOR LOWERING THE RISKS OF ALZHEIMER'S, CARDIOVASCULAR AND TYPE-2 DIABETES DISEASES”, filed on Oct. 29, 2012, (which claims priority to: U.S. Provisional Patent Application No. 61 / 742,074 entitled “CHEMICAL COMPOSITION AND ITS DELIVERY FOR LOWERING THE RISKS OF ALZHEIMER'S, CARDIOVASCULAR AND TYPE-2 DIABETES DISEASES”, filed on Aug. 1, 2012; U.S. Provisional Patent Application No. 61 / 631,071 entitl...

AI Technical Summary

Benefits of technology

This patent is about chemical compounds that can help reduce the risk of Alzheimer's, cardiovascular disease, and diabetes. These compounds can be used in various ways to lower the risk of these diseases.

Problems solved by technology

Type-1 Diabetes disease can be caused by autoimmune destruction of insulin-producing cells in the pancreas, resulting in high blood sugar.

The macrophages in fat tissues produce cytokine molecules, which can cause inflammations in the pancreas.

But Type-2 Diabetes disease not only lacks insulin, but also produces too much glucagon.

Both Type-1 and Type-2 Diabetes diseases can lead to serious complications (e.g., high blood pressure, kidney disease and premature death).

Deficiency in SorCS1 transport protein can increase risk of developing Alzheimer's disease, because amyloid precursor protein (APP) spends too much time in the region of the neuron wherein amyloid precursor protein (APP) is broken down into amyloid beta (Aβ) protein.

Glycation can cause problems in a human brain.

But obesity can create leptin resistance-thus leptin is not transported efficiently in a human brain.

Although obesity is often associated with insulin resistance and Diabetes disease, this is not always the case.

Clinical and epidemiological studies have found that Type-2 Diabetes disease and hyperinsulinaemia, increased the risk of developing Alzheimer's disease.

Images